Safety and Efficacy Study of Copaxone Administered in Combination With N-Acetylcysteine

Relapse Remitting Multiple Sclerosis Clinical Trial

Official title:
A Pilot, Multicenter, Open-label, One-group Study to Explore the Efficacy, Tolerability and Safety of the Combination of Glatiramer Acetate (GA) and N-Acetylcysteine (NAC) in Subjects With Relapsing Remitting Multiple Sclerosis (RR-MS)

Status Completed

Clinical Trial Summary

This study evaluates the effect of the therapy combining GA and NAC on disease activity as reflected by MRI parameters while assessing tolerability and safety.

Clinical Trial Description

n/a

Study Design

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

Multiple Sclerosis
Multiple Sclerosis, Relapsing-Remitting
Relapse Remitting Multiple Sclerosis
Sclerosis

Clinical Trial Details

NCT number	NCT00203099
Study type	Interventional
Source	Teva Pharmaceutical Industries
Contact
Status	Completed
Phase	Phase 2
Start date	December 2004
Completion date	June 2008

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT00203112` - Safety and Efficacy Study of Copaxone Administered in Combination With Minocycline	Phase 2
Recruiting	`NCT04857489` - Deficient T Regulatory Cell (Treg) Function in Patients With Relapsing Remitting Multiple Sclerosis
Active, not recruiting	`NCT05084638` - Study to Assess the Effect of Ofatumumab in Treatment Naïve, Very Early RRMS Patients Benchmarked Against Healthy Controls.	Phase 4
Recruiting	`NCT05705986` - Immunoregulatory Effect of Microparticle Delivered STING Agonist in the Control of Experimental Autoimmune Encephalomyelitis (EAE) and Multiple Sclerosis (MS)
Terminated	`NCT02038049` - A Study to Assess the Effect of a Single Infusion of VAY736 on Disease Activity in Patients With Relapsing-remitting Multiple Sclerosis	Phase 2